ECSP17013617A - “combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y nsaid” - Google Patents

“combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y nsaid”

Info

Publication number
ECSP17013617A
ECSP17013617A ECIEPI201713617A ECPI201713617A ECSP17013617A EC SP17013617 A ECSP17013617 A EC SP17013617A EC IEPI201713617 A ECIEPI201713617 A EC IEPI201713617A EC PI201713617 A ECPI201713617 A EC PI201713617A EC SP17013617 A ECSP17013617 A EC SP17013617A
Authority
EC
Ecuador
Prior art keywords
components
dimethylamino
phenol
propyl
ethyl
Prior art date
Application number
ECIEPI201713617A
Other languages
English (en)
Inventor
Petra Bloms-Funke
Klaus Schiene
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37025077&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP17013617(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of ECSP17013617A publication Critical patent/ECSP17013617A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/14—Acetic acid esters of monohydroxylic compounds
    • C07C69/145—Acetic acid esters of monohydroxylic compounds of unsaturated alcohols
    • C07C69/157—Acetic acid esters of monohydroxylic compounds of unsaturated alcohols containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • C07D231/48—Oxygen atom in position 3 or 5 and nitrogen atom in position 4 with hydrocarbon radicals attached to said nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una combinación que comprende como componentes (a) el compuesto 3- (3-Dimetilamino-1-etil-2-metil-propil) -fenol, y (b) uno o más fármacos antiinflamatorios no esteroideos; una sal farmacéutica que comprende dichos componentes; un compuesto derivado de dichos componentes; una formulación farmacéutica y una forma de dosificación que comprende dicha combinación, sal o compuesto; así como un método para tratar el dolor crónico o agudo, en un mamífero caracterizado porque los componentes (a) y (b) se administran simultánea o secuencialmente a un mamífero, donde el componente (a) puede administrarse antes o después del componente (b) y en el que los componentes (a) o (B) se administran al mamífero ya sea a través de la misma o de una vía de administración diferente.
ECIEPI201713617A 2006-04-28 2017-03-06 “combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y nsaid” ECSP17013617A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06008850 2006-04-28

Publications (1)

Publication Number Publication Date
ECSP17013617A true ECSP17013617A (es) 2018-03-31

Family

ID=37025077

Family Applications (2)

Application Number Title Priority Date Filing Date
EC2008008873A ECSP088873A (es) 2006-04-28 2008-11-07 Combinación farmaceutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil) fenol y nsaid
ECIEPI201713617A ECSP17013617A (es) 2006-04-28 2017-03-06 “combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y nsaid”

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EC2008008873A ECSP088873A (es) 2006-04-28 2008-11-07 Combinación farmaceutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil) fenol y nsaid

Country Status (25)

Country Link
US (4) US20090099138A1 (es)
EP (1) EP2012763B1 (es)
JP (1) JP5543200B2 (es)
KR (1) KR101517064B1 (es)
CN (4) CN102675136B (es)
AT (1) ATE502629T1 (es)
AU (1) AU2007247480B8 (es)
BR (1) BRPI0711482B8 (es)
CA (1) CA2649459C (es)
CY (1) CY1111551T1 (es)
DE (1) DE602007013380D1 (es)
DK (1) DK2012763T3 (es)
EC (2) ECSP088873A (es)
ES (1) ES2358763T3 (es)
HR (1) HRP20110271T1 (es)
IL (1) IL194885A (es)
MX (1) MX2008013828A (es)
NO (1) NO341152B1 (es)
NZ (1) NZ571939A (es)
PL (1) PL2012763T3 (es)
PT (1) PT2012763E (es)
RU (1) RU2465263C2 (es)
SI (1) SI2012763T1 (es)
WO (1) WO2007128412A1 (es)
ZA (1) ZA200810125B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55769B1 (sr) * 2007-11-23 2017-07-31 Gruenenthal Gmbh Kompozicije tapentadola
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
KR101730924B1 (ko) * 2008-09-05 2017-04-27 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
CN102438594A (zh) 2009-04-24 2012-05-02 伊休蒂卡有限公司 吲哚美辛的新剂型
WO2011124953A2 (en) 2010-04-07 2011-10-13 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
EP2992877A1 (en) 2010-06-15 2016-03-09 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
CN110015955A (zh) 2010-07-23 2019-07-16 格吕伦塔尔有限公司 3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚的盐或共晶体
EP2619174A4 (en) * 2010-09-20 2014-05-14 Ind Swift Lab Ltd PROCESS FOR THE PREPARATION OF L-PHENYL-3-DIMETHYLAMINOPROPANE DERIVATIVES
MX388963B (es) 2011-03-04 2025-03-20 Gruenenthal Gmbh Formulacion farmaceutica acuosa de tapentadol para administracion oral
CN103501775A (zh) * 2011-03-04 2014-01-08 格吕伦塔尔有限公司 他喷他多的胃肠外给药
ES2910085T3 (es) 2011-03-04 2022-05-11 Gruenenthal Gmbh Composición farmacéutica acuosa semisólida que contiene tapentadol
ES2703282T3 (es) * 2011-04-05 2019-03-07 Gruenenthal Gmbh Tapentadol para prevenir la cronificación del dolor
US20120277319A1 (en) 2011-04-29 2012-11-01 Gruenenthal Gmbh Use of Tapentadol for Inhibiting and/or Treating Depression and Anxiety
EP3300726A1 (en) * 2011-07-29 2018-04-04 Grünenthal GmbH Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US8912226B2 (en) * 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
PE20171651A1 (es) 2015-03-27 2017-11-13 Gruenenthal Chemie Formulacion estable para administracion parenteral de tapentadol
RU2611659C1 (ru) * 2015-11-18 2017-02-28 Российская Федерация, от имени которой выступает Федеральное государственное казенное учреждение "Войсковая часть 68240" Фармацевтическая композиция в виде назального спрея на основе кеторолака и способ ее получения
EP3515412B1 (en) 2016-09-23 2025-04-23 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
EP3585370A1 (en) 2017-02-23 2020-01-01 Grünenthal GmbH Tapentadol as local anesthetic
CN116253652A (zh) * 2021-12-09 2023-06-13 武汉思瓴生物科技有限公司 他喷他多的长链脂肪酸酯类衍生物、药学上可接受的盐、药物组合物及制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
AU661723B2 (en) * 1991-10-30 1995-08-03 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
CA2149317A1 (en) * 1992-12-21 1994-07-07 Richard Wilfred D'souza Compositions and method for providing improved analgesic effect
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
DE10109763A1 (de) * 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
US20040242597A1 (en) * 2001-09-19 2004-12-02 Thomas Klein Combination
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
DK3241550T3 (da) * 2002-11-22 2020-08-24 Gruenenthal Gmbh Anvendelse af (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol til behandling af inflammatoriske smerter
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform

Also Published As

Publication number Publication date
NO341152B1 (no) 2017-09-04
IL194885A0 (en) 2009-08-03
BRPI0711482B8 (pt) 2021-05-25
EP2012763B1 (en) 2011-03-23
HRP20110271T1 (hr) 2011-05-31
ATE502629T1 (de) 2011-04-15
US20090099138A1 (en) 2009-04-16
CN102671195B (zh) 2016-01-20
PL2012763T3 (pl) 2011-08-31
ECSP088873A (es) 2008-12-30
NO20084296L (no) 2008-11-13
CN101426485A (zh) 2009-05-06
CN105561311B (zh) 2019-07-16
CY1111551T1 (el) 2015-08-05
JP2009535312A (ja) 2009-10-01
AU2007247480A8 (en) 2013-04-11
AU2007247480B8 (en) 2013-04-11
DK2012763T3 (da) 2011-05-02
DE602007013380D1 (de) 2011-05-05
BRPI0711482A8 (pt) 2017-11-28
CN102675136B (zh) 2016-01-20
CA2649459A1 (en) 2007-11-15
CN105561311A (zh) 2016-05-11
WO2007128412A1 (en) 2007-11-15
CN102675136A (zh) 2012-09-19
EP2012763A1 (en) 2009-01-14
RU2008146815A (ru) 2010-06-20
JP5543200B2 (ja) 2014-07-09
CA2649459C (en) 2014-07-22
ZA200810125B (en) 2009-09-30
US20130190333A1 (en) 2013-07-25
AU2007247480A1 (en) 2007-11-15
CN101426485B (zh) 2013-02-13
PT2012763E (pt) 2011-04-29
NZ571939A (en) 2011-10-28
RU2465263C2 (ru) 2012-10-27
US20160045459A1 (en) 2016-02-18
KR101517064B1 (ko) 2015-04-30
AU2007247480B2 (en) 2013-03-21
IL194885A (en) 2012-10-31
CN102671195A (zh) 2012-09-19
BRPI0711482A2 (pt) 2012-02-14
KR20090007613A (ko) 2009-01-19
MX2008013828A (es) 2008-11-10
SI2012763T1 (sl) 2011-06-30
BRPI0711482B1 (pt) 2019-09-17
HK1127288A1 (en) 2009-09-25
ES2358763T3 (es) 2011-05-13
US20160361276A1 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
ECSP17013617A (es) “combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y nsaid”
AR117613A2 (es) Combinación farmacéutica
ECSP19047259A (es) Combinación farmacéutica para el tratamiento del dolor
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
UY32925A (es) Composiciones de corticosteroides de administración oral
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
CO6341550A2 (es) Combinacion farmaceutica que contiene el 6 - dimetilaminometil - 1 - (3-metoxi-fenil) - ciclohexano - 1,3 - diol y un nsaid.
UY31826A (es) Compuesto peptídico y su uso
ECSP099734A (es) Composición farmaceutica que comprende la combinación de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante
CL2007000485A1 (es) Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina.
AR073277A1 (es) Combinacion farmaceutica que contiene el 6-dimetilaminometil-1-(3-metoxi-fenil)-ciclohexano-1,3-diol y paracetamol, y uso
ECSP088801A (es) Composicion farmaceutica que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b para el tratamiento de la neuralgia
CO2018013792A2 (es) Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo
CL2013003671A1 (es) Composicion y combinacion farmaceutica que comprende ketorolaco y meloxicam; proceso para preparar la composicion; uso en el tratamiento de la inflamacion y el dolor.
AR072871A1 (es) Combinacion terapeutica que comprende un inhibidor de aurora quinasa y un agente antineoplasico, composicion farmaceutica